|
| 1 |
|
Conditions listed in this trial |
|
|
Leukemia |
|
|
Lymphoma |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Leukemia, B-Cell |
|
|
Leukemia, Lymphocytic, Chronic, B-Cell |
|
|
Leukemia, Lymphoid |
|
|
Lymphoma, B-Cell |
|
|
Lymphoma, Large-Cell, Immunoblastic |
|
| 3 |
|
More general conditions related to this trial |
|
|
Immune System Diseases |
|
|
Immunoproliferative Disorders |
|
|
Lymphatic Diseases |
|
|
Lymphoma, Non-Hodgkin |
|
|
Lymphoproliferative Disorders |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
| 4 |
|
Interventions listed in this trial |
|
|
anti-thymocyte globulin |
|
|
cyclophosphamide |
|
|
cyclosporine |
|
|
filgrastim |
|
|
fludarabine phosphate |
|
|
mycophenolate mofetil |
|
|
rituximab |
|
|
total-body irradiation |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Antilymphocyte Serum |
|
|
Cyclosporins |
|
|
Fludarabine |
|
|
Fludarabine monophosphate |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Alkylating Agents |
|
|
Anti-Infective Agents |
|
|
Antifungal Agents |
|
|
Antimetabolites |
|
|
Antimetabolites, Antineoplastic |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Alkylating |
|
|
Antirheumatic Agents |
|
|
Dermatologic Agents |
|
|
Enzyme Inhibitors |
|
|
Immunologic Factors |
|
|
Immunosuppressive Agents |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Myeloablative Agonists |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Therapeutic Uses |
|
| 7 |
|
Sponsors listed in this trial |
|
|
Memorial Sloan-Kettering Cancer Center |
|
|
National Cancer Institute (NCI) |
